News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CorMedix (CRMD) Granted Extension of NYSE MKT Listing



2/7/2013 9:59:47 AM

BRIDGEWATER, N.J.--(BUSINESS WIRE)--CorMedix Inc. (“CorMedix”) (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announces the receipt of notice on February 1, 2013 from the NYSE MKT LLC (the “NYSE MKT”) that the NYSE MKT granted it an extension until April 15, 2013 to regain compliance with the continued listing standards of the NYSE MKT. The NYSE MKT is continuing CorMedix’s listing pursuant to the extension. CorMedix will be subject to periodic review by the NYSE MKT during the extension period. Failure to make progress consistent with the plan or to regain compliance with continued listing standards by the end of the extension period could result in CorMedix being delisted from the NYSE MKT.

Read at BioSpace.com


comments powered by Disqus
CorMedix
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES